Submitted: 20 Feb 2017
Revision: 04 Apr 2017
Accepted: 07 Apr 2017
ePublished: 17 May 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Cardiovasc Thorac Res. 2017;9(2): 102-107.
doi: 10.15171/jcvtr.2017.17
PMID: 28740630
PMCID: PMC5516049
  Abstract View: 1050
  PDF Download: 815

Original Article

Safety and effect of high dose allopurinol in patients with severe left ventricular systolic dysfunction

Mohammad Mostafa Ansari-Ramandi 1, Majid Maleki 1, Azin Alizadehasl 1, Ahmad Amin 1, Sepideh Taghavi 1, Mohammad Javad Alemzadeh-Ansari 1, Ali Kazem Moussavi 1, Nasim Naderi 1 *

1 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran


Introduction: Allopurinol used in the treatment of gout has been shown to improve the vascular endothelial dysfunction and reduce the dysfunction of the failing heart. This study was done to evaluate the effect and safety of allopurinol in non-hyperuricemic patients with chronic severe left ventricular (LV) dysfunction.
In this study, 35 consecutive cases of non-hyperuricemic patients with chronic heart failure who had severe LV systolic dysfunction (ejection fraction of less than 35%) and were on optimal guideline directed medical therapies for at least 3 months were included. Allopurinol was administered with the dose of 300 mg po daily for 1 week and then it was up-titrated to a dose of 600 mg po daily for 3 months. Six minute walk test, strain imaging, laboratory testing were done for every patient at baseline and after 3 months treatment with allopurinol.
In this study 30 heart failure (HF) patients with a mean age of 49.3 ± 14.4 years old were evaluated. No adverse effects were reported except for one case of skin rash after 4 days treatment which was excluded from the study. Study showed significant improvement of six minute walk test of the patients from 384.5 ± 81.5 meters to 402.8 ± 89.6 meters and the global longitudinal peak strain (P < 0.001). There was also significant decrease in the level of erythrocyte sedimentation rate and N-terminal pro-brain natriuretic peptide (NT-proBNP) after 3 months.
Conclusion: Allopurinol could be of benefit in non-hyperuricemic patients with severe LV systolic dysfunction without significant adverse effects. Randomized clinical trials are needed in future to confirm the results.
Keywords: Allopurinol, Severe LV Systolic Dysfunction, Strain Imaging, Quality of Life, NT-proBNP
First Name
Last Name
Email Address
Security code

Abstract View: 1050

Your browser does not support the canvas element.

PDF Download: 815

Your browser does not support the canvas element.